Search
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnTolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506Investigational(completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes). … Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236
Categories: Experimental Unapproved Treatments for COVID-19Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115ApprovedAs these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding difficulties) which may progress … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.
Gluconic Acid
go.drugbank.com/drugs/DB13180ApprovedInvestigationalCommonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.
Mixtures: Isolyte S pH 7.4, Plasma-Lyte 148 (pH 7.4)Ethylestrenol
go.drugbank.com/drugs/DB01493ApprovedWithdrawnAn anabolic steroid with some progestational activity and little androgenic effect. [PubChem]
Categories: Anabolic Agents for Systemic UseThiethylperazine
go.drugbank.com/drugs/DB00372ApprovedInvestigationalWithdrawnA dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent ver...
Categories: Antihistamines for Systemic Use, Dopamine D2 Receptor AntagonistsDihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnThe FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942] … Dihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity.
Pesampator
go.drugbank.com/drugs/DB11843InvestigationalPF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.
Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigational[A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, Cytochrome P-450 SubstratesTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigational[L31443,L31473] It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,[L31473] an advantage that may aid in easing the pill burden often associated with chemotherapeutic … In February 2022, tepotinib was approved for use in Europe.[L42200]
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates